A Pilot Study of the Cala ONE Device for Essential Tremor

NCT03152136 | Completed Results FDA Device

• 1 other identifier: ET-13
• Study Type: interventional
• Target: 62
• Locations: 1 country
• Sites: 4

Brief Summary

Prospective, multi-center, randomized, controlled study designed to evaluate safety and repeatable effectiveness. Subjects will be randomized 2:1:1 to transcutaneous afferent patterned stimulation (TAPS), sham, or 'no intervention', respectively. Subjects randomized to the TAPS and sham arms will be blinded to their randomization assignments for the first two weeks of participation (controlled phase). After the first two weeks, all subjects will be crossed over to TAPS (open-label phase) for 2 weeks. During study participation, all subjects are to remain on a stable dosage of medications prescribed for the treatment of essential tremor, if applicable.

Conditions

Essential Tremor

Outcome Measures

Primary Outcomes (1)

• Percent Change in Tremor Power

  For TAPS and sham arms, subjects will be prompted to perform a lateral postural hold prior to entering their PGI-S score before and after each stimulation session. During this hold, the device will record motion data to objectively assess if there are any changes in tremor level.

  Mean tremor power pre stimulation over two weeks of device usage as compared to mean tremor power post stimulation over two weeks of device usage.

Other Outcomes (12)

• Change in Clinical Rating Scale for Tremor (CRST) After Stimulation

  Collected before and after in-office stimulation sessions at Week 2

• Change in Clinical Global Impression of Severity (CGI-S)

  Collected before, during, and after in-office stimulation sessions at Week 0, Week 2, and Week 4

• Clinical Global Impression of Improvement (CGI-I)

  Collected during and after in-office stimulation sessions at Week 0, Week 2, and Week 4

Study Arms (3)

TAPS

EXPERIMENTAL

Subjects will receive a Cala ONE device that delivers TAPS, transcutaneous afferent patterned stimulation.

Device: Cala ONE device

Sham

SHAM COMPARATOR

Subjects will receive a Cala ONE device that delivers sham stimulation.

Device: Cala ONE device

No Intervention

NO INTERVENTION

Subjects will not receive a Cala ONE device, and will stay on their current treatment regimen for their essential tremor.

Interventions

Cala ONE device DEVICE

The Cala ONE device is a wrist-worn stimulator which applies a tremor-customized stimulation pattern to an individual's nerves.

Sham; TAPS

Eligibility Criteria

• Age: 22 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Must be ≥22 and ≤80 years of age
• Competent and willing to provide written, informed consent to participate in the study
• A diagnosis of essential tremor as confirmed from clinical history and examination by a movement disorder neurologist
• Postural, action or intention tremor severity score of 2 or above in the dominant hand/arm as measured by the CRST rating scale
• Significant disability due to essential tremor (Bain \& Findley score of 3 or above in any one of the hand items)
• Currently or previously prescribed either propranolol or primidone for the treatment of essential tremor
• Stable dose of tremor medications for 30 days prior to study entry
• Stable dose of antidepressant medications for 90 days prior to study entry
• Willing to comply with study protocol requirements including: remaining on a stable dosage of tremor and antidepressant medications, if applicable, during the duration of the study; no significant alcohol or caffeine consumption within 12 hours of study visits; and no significant alcohol or caffeine consumption within 4 hours of twice-daily at home assessments during the controlled phase of the study

You may not qualify if:

• Moderate to severe ethanol dependence as defined by the criteria outlined in the DSM-5 (score of 4 or higher)
• Implanted electrical medical device, such as a pacemaker, defibrillator, or deep brain stimulator
• Previous thalamotomy procedure, including stereotactic thalamotomy, gamma knife radiosurgical thalamotomy, and focused ultrasound for the treatment of tremor
• Suspected or diagnosed epilepsy or other seizure disorder
• Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site
• Peripheral neuropathy affecting the tested upper extremity
• Presence of any other neurodegenerative disease like Parkinson-plus syndromes suspected on neurological examination. These include: multisystem atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease.
• Anyone suspected to have the diagnosis of idiopathic Parkinson's disease (PD). This includes excluding anyone with the presence of parkinsonian features including bradykinesia rigidity, or postural instability. Subjects who exhibit only mild resting tremor but no other symptoms or signs of PD may be included.
• Botulinum toxin injection for hand tremor within 6 months prior to study enrollment
• Are participating or have participated in another interventional clinical trial in the last 30 days which may confound the results of this study, unless approved by the Sponsor
• Are participating or have participated in another Cala Health clinical trial
• Significant alcohol or caffeine consumption within 12 hours of study enrollment, which may confound the results of the study, where significant caffeine is considered more than 95 mg (equivalent to a cup of coffee), and significant alcohol is considered more than 14 g (equivalent to 5 oz of wine, 12 oz of beer, or 1.5 oz of distilled spirits).
• Subjects unable to communicate with the investigator and staff
• Any health condition that in the investigator's opinion should preclude participation in this study
• Pregnancy or anticipated pregnancy during the course of the study

Sponsors & Collaborators

• Cala Health, Inc.: lead

Study Sites (4)

Personal Care Neurology

Oakland, California, 94611, United States

Location

Movement & Neuroperformance Center

Denver, Colorado, 80113, United States

Location

Kansas University Medical Center

Kansas City, Kansas, 66103, United States

Location

EvergreenHealth

Kirkland, Washington, 98034, United States

Location

MeSH Terms

Conditions

Essential Tremor

Condition Hierarchy (Ancestors)

Movement Disorders; Central Nervous System Diseases; Nervous System Diseases

Results Point of Contact

• Title: Paula Chidester
• Organization: Cala Health

paula@calahealth.com

650-273-7436

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: LTE60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Masking Details: The first two weeks of the study are double-blinded for the treatment and sham arms. The subjects and rating movement disorder neurologists will be blinded to the therapy allocation for the treatment and sham arms. The subjects in the 'no intervention' arm and their rating neurologists will not be blinded to their therapy allocation. The last two weeks are open-label, and all subjects will be given the option to use the Cala ONE device.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: The first two weeks are a 3-arm parallel design (treatment, sham, and 'no intervention'). The second two weeks are open-label (all subjects cross-over to treatment arm).

Study Record Dates

• First Submitted: May 7, 2017
• First Posted: May 12, 2017
• Study Start: July 26, 2017
• Primary Completion: March 8, 2018
• Study Completion: March 8, 2018
• Last Updated: April 30, 2019
• Results First Posted: April 30, 2019

Record last verified: 2019-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (4)